These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition

Pretty much everyone familiar with Gilead Sciences (NASDAQ: GILD) wants the company to make an acquisition. Many think the big biotech desperately needs one (or more) to reenergize the lethargic stock. According to a recent article on Investors.com, though, Needham analyst Alan Carr might be an exception.

Carr believes that Gilead Sciences has upside potential even without an acquisition. His premise is that expected approval of a new hepatitis C combo and positive results from a late-stage study of the bictegravir/F/TAF combo for treating HIV could jump-start the biotech's share price.

I think Carr is right that good news on these fronts could help Gilead rebound, to some extent. However, I don't think it will be nearly enough to satisfy investors. Gilead Sciences still needs to make an acquisition. The following charts don't lie.

Continue reading

Source: Fool.com